Literature DB >> 18195571

The chemokine CCL5 regulates the in vivo cell surface expression of its receptor, CCR5.

Yea-Lih Lin1, Clément Mettling, Pierre Portalès, Régine Rouzier, Jacques Clot, Jacques Reynes, Pierre Corbeau.   

Abstract

The efficiency of CCR5 as an HIV coreceptor is strongly dependent on its level of cell surface expression. Therefore, it is of major importance to identify the factors that regulate cell surface density of CCR5. Among the chemokines that bind to CCR5, and induce its internalization, CCL5 is the most abundant in vivo. We show that the level of CCL5 production is a main factor determining CD4+ T cell surface CCR5 density.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18195571     DOI: 10.1097/QAD.0b013e3282f46a6f

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  13 in total

1.  Peripheral blood T4 cell surface CCR5 density as a marker of activity in rheumatoid arthritis treated with anti-CD20 monoclonal antibody.

Authors:  Pierre Portalès; Sylvie Fabre; Thierry Vincent; Caroline Desmetz; Brigitte Réant; Danièle Noël; Jacques Clot; Christian Jorgensen; Pierre Corbeau
Journal:  Immunology       Date:  2009-03-26       Impact factor: 7.397

2.  CCR5 antagonism impacts vaccination response and immune profile in HIV-1 infection.

Authors:  Samantha J Westrop; Graeme Moyle; Akil Jackson; Mark Nelson; Sundhiya Mandalia; Nesrina Imami
Journal:  Mol Med       Date:  2012-10-24       Impact factor: 6.354

3.  Marked differences in CCR5 expression and activation levels in two South African populations.

Authors:  Anabela C P Picton; Sharon Shalekoff; Maria Paximadis; Caroline T Tiemessen
Journal:  Immunology       Date:  2012-08       Impact factor: 7.397

4.  CCR5 promoter haplotypes differentially influence CCR5 expression on natural killer and T cell subsets in ethnically divergent HIV-1 uninfected South African populations.

Authors:  Anabela C P Picton; Maria Paximadis; Caroline T Tiemessen
Journal:  Immunogenetics       Date:  2012-08-15       Impact factor: 2.846

5.  The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial.

Authors:  Peter W Hunt; Nancy S Shulman; Timothy L Hayes; Viktor Dahl; Ma Somsouk; Nicholas T Funderburg; Bridget McLaughlin; Alan L Landay; Oluwatoyin Adeyemi; Lee E Gilman; Brian Clagett; Benigno Rodriguez; Jeffrey N Martin; Timothy W Schacker; Barbara L Shacklett; Sarah Palmer; Michael M Lederman; Steven G Deeks
Journal:  Blood       Date:  2013-04-15       Impact factor: 22.113

6.  Coreceptor and cytokine concentrations may not explain differences in disease progression observed in HIV-1 clade A and D infected Ugandans.

Authors:  Edward Wright; Susan Mugaba; Paul Grant; Rosalind Parkes-Ratanshi; Lieve Van der Paal; Heiner Grosskurth; Pontiano Kaleebu
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

7.  CCR5: From Natural Resistance to a New Anti-HIV Strategy.

Authors:  Lucia Lopalco
Journal:  Viruses       Date:  2010-02-05       Impact factor: 5.818

8.  CCR5 susceptibility to ligand-mediated down-modulation differs between human T lymphocytes and myeloid cells.

Authors:  James M Fox; Richard Kasprowicz; Oliver Hartley; Nathalie Signoret
Journal:  J Leukoc Biol       Date:  2015-05-08       Impact factor: 4.962

9.  Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.

Authors:  Steven F L van Lelyveld; Julia Drylewicz; Maaike Krikke; Ellen M Veel; Sigrid A Otto; Clemens Richter; Robin Soetekouw; Jan M Prins; Kees Brinkman; Jan Willem Mulder; Frank Kroon; Ananja Middel; Jori Symons; Annemarie M J Wensing; Monique Nijhuis; José A M Borghans; Kiki Tesselaar; Andy I M Hoepelman
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

10.  The CCR5 chemokine receptor mediates vasoconstriction and stimulates intimal hyperplasia in human vessels in vitro.

Authors:  Janet J Maguire; Katie L Jones; Rhoda E Kuc; Murray C H Clarke; Martin R Bennett; Anthony P Davenport
Journal:  Cardiovasc Res       Date:  2013-12-09       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.